Warren Chow

5.8k total citations
111 papers, 2.3k citations indexed

About

Warren Chow is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Warren Chow has authored 111 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in Warren Chow's work include Sarcoma Diagnosis and Treatment (37 papers), CAR-T cell therapy research (13 papers) and Gastrointestinal Tumor Research and Treatment (12 papers). Warren Chow is often cited by papers focused on Sarcoma Diagnosis and Treatment (37 papers), CAR-T cell therapy research (13 papers) and Gastrointestinal Tumor Research and Treatment (12 papers). Warren Chow collaborates with scholars based in United States, Canada and United Kingdom. Warren Chow's co-authors include Min Guan, Chunling Jiang, George Somlo, Paul Frankel, Robert J. Morgan, James H. Doroshow, Kim Margolin, Arthur P. Staddon, Lucille Leong and Stephen Shibata and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Warren Chow

102 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Warren Chow United States 27 950 796 640 325 301 111 2.3k
Carsten Boltze Germany 29 893 0.9× 532 0.7× 750 1.2× 335 1.0× 422 1.4× 87 2.7k
Michelle Scurr United Kingdom 27 1.7k 1.8× 1.0k 1.3× 1.0k 1.6× 237 0.7× 462 1.5× 56 3.1k
Steven Attia United States 23 1.4k 1.4× 1.0k 1.3× 369 0.6× 154 0.5× 321 1.1× 140 2.1k
Kjetil Boye Norway 25 636 0.7× 678 0.9× 1.0k 1.6× 587 1.8× 268 0.9× 84 2.2k
Philippe Tanière United Kingdom 29 824 0.9× 1.1k 1.4× 1.0k 1.6× 497 1.5× 618 2.1× 94 2.6k
Dusan Kotasek Australia 28 542 0.6× 1.2k 1.5× 448 0.7× 282 0.9× 183 0.6× 104 2.3k
Stefano Serra Canada 31 615 0.6× 1.4k 1.8× 666 1.0× 420 1.3× 1.1k 3.5× 121 2.8k
Alexander J. Chou United States 25 1.1k 1.2× 726 0.9× 931 1.5× 503 1.5× 241 0.8× 61 2.4k
Seiichi Tamai Japan 28 662 0.7× 720 0.9× 840 1.3× 353 1.1× 533 1.8× 118 2.7k
W. J. Mooi Netherlands 26 840 0.9× 1.2k 1.5× 1.1k 1.7× 353 1.1× 432 1.4× 60 2.7k

Countries citing papers authored by Warren Chow

Since Specialization
Citations

This map shows the geographic impact of Warren Chow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Warren Chow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Warren Chow more than expected).

Fields of papers citing papers by Warren Chow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Warren Chow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Warren Chow. The network helps show where Warren Chow may publish in the future.

Co-authorship network of co-authors of Warren Chow

This figure shows the co-authorship network connecting the top 25 collaborators of Warren Chow. A scholar is included among the top collaborators of Warren Chow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Warren Chow. Warren Chow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Changjun, Faqing Huang, Mengmeng Liu, et al.. (2025). Targeted Treatment of Sarcomas by Single Protein Encapsulated Doxorubicin with Undetectable Cardiotoxicity and Superior Efficacy. Cancers. 17(5). 881–881.
2.
3.
Yu, Changjun, Faqing Huang, Mengmeng Liu, et al.. (2023). Single protein encapsulated SN38 for tumor-targeting treatment. Journal of Translational Medicine. 21(1). 897–897. 4 indexed citations
4.
Yoon, Janet, et al.. (2023). Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma. Journal of Personalized Medicine. 13(10). 1499–1499. 1 indexed citations
5.
Chow, Warren, et al.. (2023). Small-molecule correctors and stabilizers to target p53. Trends in Pharmacological Sciences. 44(5). 274–289. 21 indexed citations
6.
Kumar, Priyanka, Jennifer B. Goldstein, Katrine Whiteson, et al.. (2022). The cure from within? a review of the microbiome and diet in melanoma. Cancer and Metastasis Reviews. 41(2). 261–280. 12 indexed citations
7.
Patnaik, Amita, Inderjit Mehmi, James Strauss, et al.. (2021). 135P First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors. Annals of Oncology. 32. S1435–S1436. 6 indexed citations
8.
Chawla, Sant P., Sanjay Goel, Warren Chow, et al.. (2020). A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. Clinical Cancer Research. 26(16). 4225–4232. 29 indexed citations
9.
Konstantinidis, Ioannis T., Carolijn L. Nota, Zeljka Jutric, et al.. (2018). Primary liver sarcomas in the modern era: Resection or transplantation?. Journal of Surgical Oncology. 117(5). 886–891. 31 indexed citations
10.
Guan, Min, Xiwei Wu, Peiguo Chu, & Warren Chow. (2017). Fatty acid synthase reprograms the epigenome in uterine leiomyosarcomas. PLoS ONE. 12(6). e0179692–e0179692. 9 indexed citations
11.
Mackall, Crystal L., Sandra P. D’Angelo, Stephan A. Grupp, et al.. (2016). Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043). Annals of Oncology. 27. vi368–vi368. 2 indexed citations
12.
Guan, Min, Leila Su, Yate‐Ching Yuan, Haiqing Li, & Warren Chow. (2015). Nelfinavir and Nelfinavir Analogs Block Site-2 Protease Cleavage to Inhibit Castration-Resistant Prostate Cancer. Scientific Reports. 5(1). 9698–9698. 43 indexed citations
13.
Zhang, Keqiang, Kevin Chu, Xiwei Wu, et al.. (2013). Amplification of FRS2 and Activation of FGFR/FRS2 Signaling Pathway in High-Grade Liposarcoma. Cancer Research. 73(4). 1298–1307. 84 indexed citations
14.
15.
Guan, Min, Kristen Fousek, Chunling Jiang, et al.. (2011). Nelfinavir Induces Liposarcoma Apoptosis through Inhibition of Regulated Intramembrane Proteolysis of SREBP-1 and ATF6. Clinical Cancer Research. 17(7). 1796–1806. 67 indexed citations
16.
Somlo, George, Benjamin Paz, Jeannie Shen, et al.. (2007). A randomized phase II neoadjuvant trial in patients with stages II-III and inflammatory breast cancer.. Cancer Research. 67. 3515–3515. 2 indexed citations
17.
Shibata, Stephen, Warren Chow, Paul Frankel, et al.. (2006). A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. Cancer Chemotherapy and Pharmacology. 59(4). 549–557. 3 indexed citations
18.
Chow, Warren, Timothy W. Synold, Merry Tetef, et al.. (2004). Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. Cancer Chemotherapy and Pharmacology. 54(3). 241–248. 5 indexed citations
19.
Morgan, R.J., L. Leong, J R Schriber, et al.. (2001). Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Bone Marrow Transplantation. 28(9). 859–863. 6 indexed citations
20.
Tetef, Merry, Kim Margolin, Chul Ahn, et al.. (1995). Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Investigational New Drugs. 13(2). 157–162. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carsten Boltze Breakdown of academic impact, for papers by Michelle Scurr Breakdown of academic impact, for papers by Steven Attia Breakdown of academic impact, for papers by Kjetil Boye Breakdown of academic impact, for papers by Philippe Tanière Breakdown of academic impact, for papers by Dusan Kotasek Breakdown of academic impact, for papers by Stefano Serra Breakdown of academic impact, for papers by Alexander J. Chou Breakdown of academic impact, for papers by Seiichi Tamai Breakdown of academic impact, for papers by W. J. Mooi
Rankless by CCL
2026